{"title":"Evaluation of simple molecular methods for distinction of the newly emerging dermatophyte Trichophyton indotineae.","authors":"Shima Aboutalebian, Zahra Jahanshiri, Mohammad Reza Shidfar, Mostafa Chadeganipour, Shahla Shadzi, Mahboobeh Kharazi, Mahzad Erami, Zahra Mirhendi, Hossein Mirhendi","doi":"10.1093/mmy/myaf071","DOIUrl":null,"url":null,"abstract":"<p><p>Trichophyton indotineae has emerged as a significant global public health concern due to its role in recalcitrant dermatophytosis and antifungal treatment failure. Precise identification of T. indotineae is essential for timely and effective therapy, and for curbing the spread of antifungal resistance. However, current routine diagnostic methods are limited to reliably distinguish T. indotineae from other closely related dermatophytes. This study aimed to develop and evaluate three simple, cost-effective molecular methods for the accurate differentiation of T. indotineae. In silico analyses were performed to identify specific restriction enzyme cut sites within the internal transcribed spacer (ITS) region and the topoisomerase II gene of T. indotineae. A total of 430 dermatophyte isolates, including 267 previously identified by ITS sequencing and 163 clinical isolates of unknown identity, were subjected to PCR amplification of ITS and topoisomerase II followed by restriction fragment length polymorphism (PCR-RFLP) analysis using EarI (Eam11041) and BsuRI (HaeIII), respectively. Additionally, a previously described T. indotineae-specific PCR assay was evaluated. The enzyme EarI digested the ITS region of T. indotineae, producing a distinct PCR-RFLP pattern; likewise, BsuRI digested the topoisomerase II gene, enabling accurate differentiation of T. indotineae. The isolates previously identified by ITS sequencing were correctly classified by both methods, achieving high sensitivity and specificity. The T. indotineae-specific PCR assay demonstrated high sensitivity, although faint cross-reactivity was observed with T. tonsurans isolates. The ITS-PCR-RFLP and topoisomerase II-PCR-RFLP methods demonstrated high accuracy, affordability, and speed for the reliable identification of T. indotineae, making them suitable for routine use in clinical laboratories, especially in resource-limited settings. Although the T. indotineae-specific PCR assay showed high sensitivity, occasional cross-reactivity with T. tonsurans suggests that it should be interpreted with caution and ideally used alongside confirmatory tests.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myaf071","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Trichophyton indotineae has emerged as a significant global public health concern due to its role in recalcitrant dermatophytosis and antifungal treatment failure. Precise identification of T. indotineae is essential for timely and effective therapy, and for curbing the spread of antifungal resistance. However, current routine diagnostic methods are limited to reliably distinguish T. indotineae from other closely related dermatophytes. This study aimed to develop and evaluate three simple, cost-effective molecular methods for the accurate differentiation of T. indotineae. In silico analyses were performed to identify specific restriction enzyme cut sites within the internal transcribed spacer (ITS) region and the topoisomerase II gene of T. indotineae. A total of 430 dermatophyte isolates, including 267 previously identified by ITS sequencing and 163 clinical isolates of unknown identity, were subjected to PCR amplification of ITS and topoisomerase II followed by restriction fragment length polymorphism (PCR-RFLP) analysis using EarI (Eam11041) and BsuRI (HaeIII), respectively. Additionally, a previously described T. indotineae-specific PCR assay was evaluated. The enzyme EarI digested the ITS region of T. indotineae, producing a distinct PCR-RFLP pattern; likewise, BsuRI digested the topoisomerase II gene, enabling accurate differentiation of T. indotineae. The isolates previously identified by ITS sequencing were correctly classified by both methods, achieving high sensitivity and specificity. The T. indotineae-specific PCR assay demonstrated high sensitivity, although faint cross-reactivity was observed with T. tonsurans isolates. The ITS-PCR-RFLP and topoisomerase II-PCR-RFLP methods demonstrated high accuracy, affordability, and speed for the reliable identification of T. indotineae, making them suitable for routine use in clinical laboratories, especially in resource-limited settings. Although the T. indotineae-specific PCR assay showed high sensitivity, occasional cross-reactivity with T. tonsurans suggests that it should be interpreted with caution and ideally used alongside confirmatory tests.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.